|
1
|
Molyneux EM, Rochford R, Griffin B, Newton
R, Jackson G, Menon G, Harrison CJ, Israels T and Bailey S:
Burkitt's lymphoma. Lancet. 379:1234–1244. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Boxer LM and Dang CV: Translocations
involving c-myc and c-myc function. Oncogene. 20:5595–5610. 2001.
View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Fang Y and Fullwood MJ: Roles, functions,
and mechanisms of long non-coding RNAs in cancer. Genomics
Proteomics Bioinformatics. 14:42–54. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Dykes IM and Emanueli C: Transcriptional
and post-transcriptional gene regulation by long non-coding RNA.
Genomics Proteomics Bioinformatics. 15:177–186. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Rodríguez-Malavé NI and Rao DS: Long
noncoding RNAs in hematopoietic malignancies. Brief Funct Genomics.
15:227–238. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Shtivelman E and Bishop JM: Effects of
translocations on transcription from PVT. Mol Cell Biol.
10:1835–1839. 1990. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Huppi K and Siwarski D: Chimeric
transcripts with an open reading frame are generated as a result of
translocation to the Pvt-1 region in mouse B-cell tumors. Int J
Cancer. 59:848–851. 1994. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Wang BJ, Ding HW and Ma GA: Long noncoding
RNA PVT1 promotes melanoma progression via endogenous sponging
miR-26b. Oncol Res. 26:675–681. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Ding C, Yang Z, Lv Z, Du C, Xiao H, Peng
C, Cheng S, Xie H, Zhou L, Wu J and Zheng S: Long non-coding RNA
PVT1 is associated with tumor progression and predicts recurrence
in hepatocellular carcinoma patients. Oncol Lett. 9:955–963. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Wang F, Yuan JH, Wang SB, Yang F, Yuan SX,
Ye C, Yang N, Zhou WP, Li WL, Li W and Sun SH: Oncofetal long
noncoding RNA PVT1 promotes proliferation and stem cell-like
property of hepatocellular carcinoma cells by stabilizing NOP2.
Hepatology. 60:1278–1290. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Zhou Q, Chen J, Feng J and Wang J: Long
noncoding RNA PVT1 modulates thyroid cancer cell proliferation by
recruiting EZH2 and regulating thyroid-stimulating hormone receptor
(TSHR). Tumour Biol. 37:3105–3113. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Takahashi Y, Sawada G, Kurashige J, Uchi
R, Matsumura T, Ueo H, Takano Y, Eguchi H, Sudo T, Sugimachi K, et
al: Amplification of PVT-1 is involved in poor prognosis via
apoptosis inhibition in colorectal cancers. Brit J Cancer.
110:164–171. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Tseng YY, Moriarity BS, Gong W, Akiyama R,
Tiwari A, Kawakami H, Ronning P, Reuland B, Guenther K, Beadnell
TC, et al: PVT1 dependence in cancer with MYC copy-number increase.
Nature. 512:82–86. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Huang F, Chen W, Peng J, Li Y, Zhuang Y,
Zhu Z, Shao C, Yang W, Yao H and Zhang S: LncRNA PVT1 triggers
Cyto-protective autophagy and promotes pancreatic ductal
adenocarcinoma development via the miR-20a-5p/ULK1 Axis. Mol
Cancer. 17:982018. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Ghesquières H, Larrabee BR, Casasnovas O,
Maurer MJ, McKay JD, Ansell SM, Montgomery D, Asmann YW, Farrell K,
Verney A, et al: A susceptibility locus for classical Hodgkin
lymphoma at 8q24 near MYC/PVT1 predicts patient outcome in two
independent cohorts. Brit J Haematol. 180:286–290. 2018. View Article : Google Scholar
|
|
16
|
Cerhan JR, Berndt SI, Vijai J, Ghesquières
H, McKay J, Wang SS, Wang Z, Yeager M, Conde L, de Bakker PI, et
al: Genome-wide association study identifies multiple
susceptibility loci for diffuse large B cell lymphoma. Nat Genet.
46:1233–1238. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Livak KJ and Schmittgen TD: Analysis of
relative gene expression data using real-time quantitative PCR and
the 2 (-Delta Delta C(T)) method. Methods. 25:402–408. 2001.
View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Zhang Y, Mo WJ, Wang X, Zhang TT, Qin Y,
Wang HL, Chen G, Wei DM and Dang YW: Microarray-based
bioinformatics analysis of the prospective target gene network of
key miRNAs influenced by long non-coding RNA PVT1 in HCC. Oncol
Rep. 40:226–240. 2018.PubMed/NCBI
|
|
19
|
Zhang Y, Dang YW, Wang X, Yang X, Zhang R,
Lv ZL and Chen G: Comprehensive analysis of long non-coding RNA
PVT1 gene interaction regulatory network inhepatocellular carcinoma
using gene microarray and bioinformatics. Am J Transl Res.
9:3904–3917. 2017.PubMed/NCBI
|
|
20
|
Paci P, Colombo T and Farina L:
Computational analysis identifies a sponge interaction network
between long non-coding RNAs and messenger RNAs in human breast
cancer. BMC Syst Biol. 8:832014. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Kong R, Zhang EB, Yin DD, You LH, Xu TP,
Chen WM, Xia R, Wan L, Sun M, Wang ZX, et al: Long noncoding RNA
PVT1 indicates a poor prognosis of gastric cancer and promotes cell
proliferation through epigenetically regulating p15 and p16. Mol
Cancer. 14:822015. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Bretones G, Delgado MD and León J: Myc and
cell cycle control. Biochim Biophys Acta. 1849:506–516. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Yang Y Xue K, Li Z, Zheng W, Dong W, Song
J, Sun S, Ma T and Li W: c-Myc regulates the CDK1/cyclin B1
dependent-G2/M cell cycle progression by histone H4 acetylation in
Raji cells. Int J Mol Med. 41:3366–3378. 2018.PubMed/NCBI
|
|
24
|
Dang CV: MYC on the path to cancer. Cell.
149:22–35. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Wang Z, Yang B, Zhang M, Guo W, Wu Z, Wang
Y, Jia L, Li S; Cancer Genome Atlas Research Network, ; Xie W and
Yang D: lncRNA epigenetic landscape analysis identifies EPIC1 as an
oncogenic lncRNA that interacts with MYC and promotes cell-cycle
progression in cancer. Cancer Cell. 33:706–720.e9. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Dutto I, Tillhon M, Cazzalini O, Stivala
LA and Prosperi E: Biology of the cell cycle inhibitor p21
(CDKN1A): Molecular mechanisms and relevance in chemical
toxicology. Arch Toxicol. 89:155–178. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Cazzalini O, Scovassi AI, Savio M, Stivala
LA and Prosperi E: Multiple roles of the cell cycle inhibitor p21
(CDKN1A) in the DNA damage response. Mutat Res. 704:12–20. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Perucca P, Cazzalini O, Madine M, Savio M,
Laskey RA, Vannini V, Prosperi E and Stivala LA: Loss of p21 CDKN1A
impairs entry to quiescence and activates a DNA damage response in
normal fibroblasts induced to quiescence. Cell Cycle. 8:105–114.
2009. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Yan C, Chen Y, Kong W, Fu L, Liu Y, Yao Q
and Yuan Y: PVT1-derived miR-1207-5p promotes breast cancer cell
growth by targeting STAT6. Cancer Sci. 108:868–876. 2017.
View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Cui M, Chang Y, Fang QG, Du W, Wu JF, Wang
JH, Liu ST and Luo SX: Non-coding RNA Pvt1 promotes cancer stem
cell-like traits in nasopharyngeal cancer via inhibiting miR-1207.
Pathol Oncol Res. 2018. View Article : Google Scholar
|
|
31
|
Wu BQ, Jiang Y, Zhu F, Sun DL and He XZ:
Long noncoding RNA PVT1 promotes EMT and cell proliferation and
migration through downregulating p21 in pancreatic cancer cells.
Technol Cancer Res Treat. 1:15330346177005592017.
|
|
32
|
Cui D, Yu CH, Liu M, Xia QQ, Zhang YF and
Jiang WL: Long non-coding RNA PVT1 as a novel biomarker for
diagnosis and prognosis of non-small cell lung cancer. Tumor Biol.
37:4127–4134. 2016. View Article : Google Scholar
|
|
33
|
Bennin DA, Don AS, Brake T, McKenzie JL,
Rosenbaum H, Ortiz L, DePaoli-Roach AA and Horne MC: Cyclin G2
associates with protein phosphatase 2A catalytic and regulatory B′
subunits in active complexes and induces nuclear aberrations and a
G1/S phase cell cycle arrest. J Biol Chem. 277:27449–27467. 2002.
View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Hasegawa S, Nagano H, Konno M, Eguchi H,
Tomokuni A, Tomimaru Y, Wada H, Hama N, Kawamoto K, Kobayashi S, et
al: Cyclin G2: A novel independent prognostic marker in pancreatic
cancer. Oncol Lett. 10:2986–2990. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Yin G, Zhou H, Xue Y, Yao B and Zhao W:
MicroRNA-340 promotes the tumor growth of human gastric cancer by
inhibiting cyclin G2. Oncol Rep. 36:1111–1118. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Zimmermann M, Arachchige-Don AP, Donaldson
MS, Patriarchi T and Horne MC: Cyclin G2 promotes cell cycle arrest
in breast cancer cells responding to fulvestrant and metformin and
correlates with patient survival. Cell Cycle. 15:3278–3295. 2016.
View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Cui DW, Cheng YJ, Jing SW and Sun GG:
Effect of cyclin G2 on proliferative ability of prostate cancer
PC-3 cell. Tumour Biol. 35:3017–3024. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Helmbold H, Galderisi U and Bohn W: The
switch from pRb/p105 to Rb2/p130 in DNA damage and cellular
senescence. J Cell Physiol. 227:508–513. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Pentimalli F, Forte IM, Esposito L,
Indovina P, Iannuzzi CA, Alfano L, Costa C, Barone D, Rocco G and
Giordano A: RBL2/p130 is a direct AKT target and is required to
induce apoptosis upon AKT inhibition in lung cancer and
mesothelioma cell lines. Oncogene. 37:3657–3671. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Nalepa G, Barnholtz-Sloan J, Enzor R, Dey
D, He Y, Gehlhausen JR, Lehmann AS, Park SJ, Yang Y, Yang X, et al:
The tumor suppressor CDKN3 controls mitosis. J Cell Biol.
201:997–1012. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Yu C, Cao H, He X, Sun P, Feng Y, Chen L
and Gong H: Cyclin-dependent kinase inhibitor 3 (CDKN3) plays a
critical role in prostate cancer via regulating cell cycle and DNA
replication signaling. Biomed Pharmacother. 96:1109–1118. 2017.
View Article : Google Scholar : PubMed/NCBI
|
|
42
|
Bortner DM and Rosenberg MP: Induction of
mammary gland hyperplasia and carcinomas in transgenic mice
expressing human cyclin E. Mol Cell Biol. 17:453–459. 1997.
View Article : Google Scholar : PubMed/NCBI
|
|
43
|
Ma Y, Fiering S, Black C, Liu X, Yuan Z,
Memoli VA, Robbins DJ, Bentley HA, Tsongalis GJ, Demidenko E, et
al: Transgenic cyclin E triggers dysplasia and multiple pulmonary
adenocarcinomas. Proc Natl Acad Sci USA. 104:4089–4094. 2007.
View Article : Google Scholar : PubMed/NCBI
|
|
44
|
Loeb KR, Kostner H, Firpo E, Norwood T, D
Tsuchiya K, Clurman BE and Roberts JM: A mouse model for cyclin
E-dependent genetic instability and tumorigenesis. Cancer Cell.
8:35–47. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
45
|
Santarius T, Shipley J, Brewer D, Stratton
MR and Cooper CS: A census of amplified and overexpressed human
cancer genes. Nat Rev Cancer. 10:59–64. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
46
|
Cheng G, Zhang L, Lv W, Dong C, Wang Y and
Zhang J: Overexpression of cyclin D1 in meningioma is associated
with malignancy grade and causes abnormalities in apoptosis,
invasion and cell cycle progression. Med Oncol. 32:4392015.
View Article : Google Scholar : PubMed/NCBI
|
|
47
|
Hall M, Bates S and Peters G: Evidence for
different modes of action of cyclin-dependent kinase inhibitors:
p15 and p16 bind to kinases, p21 and p27 bind to cyclins. Oncogene.
11:1581–1588. 1995.PubMed/NCBI
|
|
48
|
Li W, Zheng Z, Chen H, Cai Y and Xie W:
Knockdown of long non-coding RNA PVT1 induces apoptosis and cell
cycle arrest in clear cell renal cell carcinoma through the
epidermal growth factor receptor pathway. Oncol Lett. 15:7855–7863.
2018.PubMed/NCBI
|
|
49
|
Chen L, Ma D, Li Y, Li X, Zhao L, Zhang J
and Song Y: Effect of long non-coding RNA PVT1 on cell
proliferation and migration in melanoma. Int J Mol Med.
41:1275–1282. 2018.PubMed/NCBI
|
|
50
|
Kapanidou M, Curtis NL and Bolanos-Garcia
VM: Cdc20: At the crossroads between chromosome segregation and
mitotic exit. Trends Biochem Sci. 42:193–205. 2017. View Article : Google Scholar : PubMed/NCBI
|
